MEKanistic Therapeutics Overview
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5M
- Investors
-
3
MEKanistic Therapeutics General Information
Description
Operator of a biotechnology company intended to develop cancer therapeutics. The company uses computational tools to design medication used to block key pathways to signal cancer cell growth, enabling patients to access multi-compound treatments.
Contact Information
Website
www.mekanistic.comCorporate Office
- 1015 Glenwood Avenue
- Fourth Floor
- Minneapolis, MN 55405
- United States
Corporate Office
- 1015 Glenwood Avenue
- Fourth Floor
- Minneapolis, MN 55405
- United States
MEKanistic Therapeutics Timeline
MEKanistic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 02-Jun-2022 | $5M | Completed | Generating Revenue | ||
| 4. Grant | 01-Sep-2021 | Completed | Startup | |||
| 3. Early Stage VC | 12-Mar-2019 | Completed | Startup | |||
| 2. Grant | 01-Feb-2017 | $275K | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup |
MEKanistic Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
MEKanistic Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MEKanistic Therapeutics Patents
MEKanistic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240239764-A1 | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors | Pending | 22-Dec-2020 |
MEKanistic Therapeutics Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Neal Meyer | Chief Financial Officer | |
| Christopher Whitehead Ph.D | Co-Founder & Chief Operating Officer | |
| Judith Leopold Ph.D | Co-Founder, Chief Strategy Officer & Chief Scientific Officer | |
| Danny Cunagin | Chief Executive Officer |
MEKanistic Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MEKanistic Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Invenshure | Accelerator/Incubator | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Innovation Partnerships | Venture Capital | Minority |
MEKanistic Therapeutics FAQs
-
Who is the founder of MEKanistic Therapeutics?
Christopher Whitehead Ph.D and Judith Leopold Ph.D are the founders of MEKanistic Therapeutics.
-
Who is the CEO of MEKanistic Therapeutics?
Danny Cunagin is the CEO of MEKanistic Therapeutics.
-
Where is MEKanistic Therapeutics headquartered?
MEKanistic Therapeutics is headquartered in Minneapolis, MN.
-
What is the size of MEKanistic Therapeutics?
MEKanistic Therapeutics has 7 total employees.
-
What industry is MEKanistic Therapeutics in?
MEKanistic Therapeutics’s primary industry is Drug Discovery.
-
Is MEKanistic Therapeutics a private or public company?
MEKanistic Therapeutics is a Private company.
-
What is the current valuation of MEKanistic Therapeutics?
The current valuation of MEKanistic Therapeutics is .
-
What is MEKanistic Therapeutics’s current revenue?
The current revenue for MEKanistic Therapeutics is .
-
How much funding has MEKanistic Therapeutics raised over time?
MEKanistic Therapeutics has raised $5M.
-
Who are MEKanistic Therapeutics’s investors?
Invenshure, U.S. Department of Health and Human Services, and Innovation Partnerships have invested in MEKanistic Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
